PDS Biotechnology Corporation held its annual meeting of stockholders on June 11, 2025. During the meeting, stockholders approved an amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan. Additionally, the appointment of KPMG US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The compensation of the Company's named executive officers was also approved by a non-binding advisory vote.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.